DR-01

DRUG3 trials

Sponsors

Dren Bio

Conditions

Aggressive NK Cell LeukemiaAlopecia AreataCutaneous PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)Cytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)Enteropathy-Associated T-Cell LymphomaExtranodal NK/T Cell Lymphoma, Nasal TypeHealthy VolunteerHepatosplenic T-cell Lymphoma

Phase 1

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

RecruitingNCT05475925

Dren BioAggressive NK Cell Leukemia, Cutaneous PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker), Cytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker) +10

Start: 2022-07-13End: 2026-12-01Target: 200Updated: 2026-06-17

A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo

Active, not recruitingNCT06602232

Dren BioAlopecia Areata, Vitiligo

Start: 2024-10-30End: 2027-05-01Updated: 2026-07-08

A Study of Subcutaneous DR-01 in Healthy Volunteers

CompletedNCT06766864

Dren BioHealthy Volunteer

Start: 2025-03-03End: 2025-08-27Updated: 2025-09-29

Related Papers

Initial clinical data from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with large granular lymphocytic leukemia

Blood2025-11-031 citations

Updated clinical data and biomarker analyses from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with relapsed/refractory cytotoxic lymphomas

Blood2025-11-03

Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization

Blood2024-11-057 citations